Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.36 |
| ▸ | SYK | P43405 | 7/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843420 | 0.89 | TEAD1 (0.41) | TEAD1YAP1TLR2TLR1 | |
| SCHEMBL22843403 | 0.88 | TEAD1 (0.52) | TEAD1YAP1MAP3K12SYKAR | |
| SCHEMBL22718287 | 0.87 | CDK5 (0.38) | TEAD1YAP1MAP3K12SYK | |
| SCHEMBL22843436 | 0.86 | TEAD1 (0.40) | TEAD1YAP1MAP3K12TLR2TLR1 | |
| SCHEMBL22843443 | 0.85 | TEAD1 (0.40) | TEAD1YAP1MAP3K12SYKAR | |
| SCHEMBL22718177 | 0.85 | TEAD1 (0.55) | TEAD1YAP1MAP3K12SYKIDH2 | |
| SCHEMBL22843441 | 0.78 | TEAD1 (0.51) | TEAD1YAP1MAP3K12SYKAR | |
| SCHEMBL22843398 | 0.78 | GABRA2 (0.37) | — | |
| SCHEMBL22843480 | 0.77 | TAS2R14 (0.37) | TEAD1SYKARIDH2 | |
| SCHEMBL22843430 | 0.76 | TEAD1 (0.54) | TEAD1YAP1TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAP3K12 1239/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAP3K12 1239/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885MAP3K12 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.